Drew Dennison is Managing director at Lightchain Capital, LLC, the family office for Scottrade Founder and former chief executive officer Rodger Riney. At Lightchain, Dennison is responsible for venture capital investments in the life science and technology sectors.
He also assists the Riney Foundations with their philanthropic endeavors. Previously, Dennison served as the chief operating officer and chief financial officer at Scottrade Financial Services, Inc.
He led the company's operations, technology, operations, finance, and strategic planning functions and worked at the company for over a decade.
Dennison led the sale of Scottrade to TD Ameritrade, then co-led the integration project, successfully combining the two companies.
In addition, Dennison serves as chairman of the board of CareVet Holdings and as a board member of FinTech Studios.
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer.
The company's next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Arch Oncology's lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the company is advancing a number of pipeline programs, including anti-signal regulatory protein antibodies.
Arch Oncology's leadership team has successfully developed new drugs for patients before and is backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3x5 RiverVest Partners II-B, and Lightchain.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval